GLP-1s take bite out of stomach weight-loss surgeries: Research
Key takeaways
- A new study published in JAMA Surgery examined trends in the use of metabolic and bariatric surgery in the U.S. between 2022 and 2024.
- The findings align with a separate recent study from Loyola University Chicago, which found the number of metabolic and bariatric surgeries in the U.S. dropped below 200,000 in 2024 for the first time since 2020.
- Researchers reported a more than 20 percent decline between 2023 and 2024, falling from 217,387 procedures to 177,297.
Why this matters: political developments that affect policy direction and public trust.
A new study published in JAMA Surgery examined trends in the use of metabolic and bariatric surgery in the U.S. between 2022 and 2024. As use of GLP-1 drugs increased by 140.4 percent during that period, bariatric surgery rates fell by 34 percent, researchers found after analyzing data from 11.7 million patients diagnosed with obesity or diabetes.
The findings align with a separate recent study from Loyola University Chicago, which found the number of metabolic and bariatric surgeries in the U.S. dropped below 200,000 in 2024 for the first time since 2020.
Researchers reported a more than 20 percent decline between 2023 and 2024, falling from 217,387 procedures to 177,297.